{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:14:17Z","timestamp":1784121257261,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jgar.2024.10.263","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:36:52Z","timestamp":1731584212000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Monte Carlo simulation for dosage optimization of the best available therapy for bloodstream infections secondary to carbapenemase-producing Klebsiella pneumoniae in critically ill patients"],"prefix":"10.1016","volume":"39","author":[{"given":"Sujareenoot","family":"Suya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3486-8591","authenticated-orcid":false,"given":"Worapong","family":"Nasomsong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichai","family":"Santimaleeworagun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piraporn","family":"Juntanawiwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tassananwan","family":"Chatreewonanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5839-440X","authenticated-orcid":false,"given":"Weerayuth","family":"Saelim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.10.263_bib0001","doi-asserted-by":"crossref","first-page":"ofv050","DOI":"10.1093\/ofid\/ofv050","article-title":"Treatment options for carbapenem-resistant Enterobacteriaceae infections","volume":"2","author":"Morrill","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2024.10.263_bib0002","series-title":"2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","first-page":"12","year":"2024"},{"key":"10.1016\/j.jgar.2024.10.263_bib0003","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.10.263_bib0004","unstructured":"National Antimicrobial Resistance Surveillance Center, Thailand (NARST). Antibiogram: antimicrobial resistance 2000-2022(12M). 2022, Available from: http:\/\/narst.dmsc.moph.go.th. Accessed 10-7-2024."},{"key":"10.1016\/j.jgar.2024.10.263_bib0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/IDR.S391409","article-title":"Epidemiology and mortality analysis related to carbapenem-resistant Enterobacterales in patients after admission to intensive care units: an observational study","volume":"16","author":"Yoo","year":"2023","journal-title":"Infect Drug Resist"},{"issue":"7","key":"10.1016\/j.jgar.2024.10.263_bib0006","doi-asserted-by":"crossref","first-page":"ofy150","DOI":"10.1093\/ofid\/ofy150","article-title":"Association between Carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis","volume":"5","author":"Martin","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2024.10.263_bib0007","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.2147\/DDDT.S321147","article-title":"The potential use of ceftazidime-avibactam against carbapenem resistant Klebsiella pneumoniae clinical isolates harboring different carbapenemase types in a Thai university hospital","volume":"15","author":"Nasomsong","year":"2021","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.jgar.2024.10.263_bib0008","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.2147\/IDR.S363588","article-title":"Association between types of carbapenemase and clinical outcomes of infection due to carbapenem resistance Enterobacterales","volume":"15","author":"Pudpong","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2024.10.263_bib0009","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3390\/antibiotics10060736","article-title":"The synergistic activity and optimizing doses of Tigecycline in combination with aminoglycosides against clinical carbapenem-resistant Klebsiella pneumoniae isolates","volume":"10","author":"Nulsopapon","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2024.10.263_bib0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.10.263_bib0011","doi-asserted-by":"crossref","first-page":"550456","DOI":"10.3389\/fcimb.2021.550456","article-title":"Critically ill vs. non-critically ill patients with COVID-19 pneumonia: clinical features, laboratory findings, and prediction","volume":"11","author":"Hong","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jgar.2024.10.263_bib0012","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","article-title":"Multiplex PCR for detection of acquired carbapenemase genes","volume":"70","author":"Poirel","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.10.263_bib0013","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 34 th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, USA, 2024. Available from: https:\/\/clsi.org. Accessed 10-7-2024."},{"key":"10.1016\/j.jgar.2024.10.263_bib0014","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, 2024. Available from: https:\/\/www.eucast.org. Accessed 10-7-2024."},{"key":"10.1016\/j.jgar.2024.10.263_bib0015","doi-asserted-by":"crossref","first-page":"622","DOI":"10.21037\/apm.2019.09.11","article-title":"Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro","volume":"8","author":"Zhang","year":"2019","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jgar.2024.10.263_bib0016","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/cid\/cis969","article-title":"Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase\u2013producing K. pneumoniae in intensive care unit","volume":"56","author":"Sbrana","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.10.263_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2253-13-13","article-title":"KPC\u20143 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients","volume":"13","author":"Di Carlo","year":"2013","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.jgar.2024.10.263_bib0018","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bjid.2017.10.006","article-title":"Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis","volume":"22","author":"Abboud","year":"2018","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jgar.2024.10.263_bib0019","series-title":"Antibiotics in laboratory medicine","first-page":"365","article-title":"Antimicrobial combinations","author":"Pillai","year":"2005"},{"key":"10.1016\/j.jgar.2024.10.263_bib0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.10.263_bib0021","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/FTD.0b013e3181f675c2","article-title":"Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients","volume":"32","author":"Delattre","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jgar.2024.10.263_bib0022","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/FTD.0b013e31818b6b2f","article-title":"Suboptimal aminoglycoside dosing in critically ill patients","volume":"30","author":"Rea","year":"2008","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.jgar.2024.10.263_bib0023","doi-asserted-by":"crossref","first-page":"e02273","DOI":"10.1128\/AAC.02273-17","article-title":"Population pharmacokinetics of high-dose Tigecycline in patients with sepsis or septic shock","volume":"62","author":"Borsuk-De Moor","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jgar.2024.10.263_bib0024","doi-asserted-by":"crossref","first-page":"e00345","DOI":"10.1128\/AAC.00345-17","article-title":"Population pharmacokinetics of Tigecycline in critically ill patients with severe infections","volume":"61","author":"Xie","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.10.263_bib0025","first-page":"1","article-title":"Optimal tigecycline dosage regimens in patients infected with carbapenem-resistant Enterobacteriaceae","volume":"14","author":"Santimaleeworagun","year":"2020","journal-title":"Sci Eng Health Stud"},{"key":"10.1016\/j.jgar.2024.10.263_bib0026","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jac\/dkx522","article-title":"Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints","volume":"73","author":"Tsala","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.10.263_bib0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ccc.2010.11.006","article-title":"Optimizing aminoglycoside use","volume":"27","author":"Craig","year":"2011","journal-title":"Crit Care Clin"},{"issue":"11","key":"10.1016\/j.jgar.2024.10.263_bib0028","doi-asserted-by":"crossref","first-page":"e00993","DOI":"10.1128\/AAC.00993-19","article-title":"Amikacin initial dose in critically ill patients: a nonparametric approach to optimize a priori pharmacokinetic\/pharmacodynamic target attainments in individual patients","volume":"63","author":"Boidin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.10.263_bib0029","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2024.10.263_bib0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/1120009X.2018.1516270","article-title":"In-vitro activities of imipenem\u2013colistin, imipenem\u2013tigecycline, and tigecycline\u2013colistin combinations against carbapenem-resistant Enterobacteriaceae*","volume":"30","author":"Dundar","year":"2018","journal-title":"J Chemother"},{"issue":"3","key":"10.1016\/j.jgar.2024.10.263_bib0031","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/antibiotics11030355","article-title":"Antimicrobial activity profiles and potential antimicrobial regimens against carbapenem-resistant Enterobacterales isolated from multi-centers in western Thailand","volume":"11","author":"Nulsopapon","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2024.10.263_bib0032","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jmii.2016.03.003","article-title":"Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: combination of tigecycline or doxycycline and gentamicin or amikacin","volume":"52","author":"Tang","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"issue":"50","key":"10.1016\/j.jgar.2024.10.263_bib0033","doi-asserted-by":"crossref","first-page":"2200926","DOI":"10.2807\/1560-7917.ES.2022.27.50.2200926","article-title":"Increase in NDM-1 and NDM-1\/OXA-48-producing Klebsiella pneumoniae in Germany associated with the war in Ukraine, 2022","volume":"27","author":"Sandfort","year":"2022","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2024.10.263_bib0034","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review","volume":"41","author":"Yaghoubi","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.10.263_bib0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.idc.2016.02.011","article-title":"Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases","volume":"30","author":"Doi","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jgar.2024.10.263_bib0036","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/14787210.2017.1316193","article-title":"Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility","volume":"15","author":"Zavascki","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2024.10.263_bib0037","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14787210.2017.1268529","article-title":"Once daily high dose tigecycline\u2014pharmacokinetic\/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited","volume":"15","author":"Cunha","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"12","key":"10.1016\/j.jgar.2024.10.263_bib0038","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3390\/antibiotics10121454","article-title":"Dose optimization of colistin: a systematic review","volume":"10","author":"Haseeb","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2024.10.263_bib0039","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/cid\/civ964","article-title":"Updated US and European dose recommendations for intravenous colistin: how do they perform?","volume":"62","author":"Nation","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.10.263_bib0040","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2024.10.263_bib0041","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/antibiotics8030125","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) simulation for dosage optimization of colistin against carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Escherichia coli","volume":"8","author":"Jitaree","year":"2019","journal-title":"Antibiotics"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524004417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524004417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T13:25:57Z","timestamp":1734701157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524004417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":41,"alternative-id":["S2213716524004417"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.10.263","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monte Carlo simulation for dosage optimization of the best available therapy for bloodstream infections secondary to carbapenemase-producing Klebsiella pneumoniae in critically ill patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.10.263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}